Adamas Pharma (ADMS)

NASDAQ
8.220
0.000(0.00%)
  • Volume:
    0
  • Day's Range:
    8.180 - 8.250
  • 52 wk Range:
    4.020 - 8.250
Trading near 52-week High

ADMS Overview

Prev. Close
8.22
Day's Range
8.18-8.25
Revenue
67.18M
Open
8.24
52 wk Range
4.02-8.25
EPS
-1.7
Volume
0
Market Cap
376.37M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,151,400
P/E Ratio
-
Beta
2.81
1-Year Change
92.96%
Shares Outstanding
45,786,965
Next Earnings Date
-
What is your sentiment on Adamas Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Adamas Pharma News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Adamas Pharma Analysis

Adamas Pharma Company Profile

Adamas Pharma Company Profile

Employees
138

Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary
  • Juat in: Supernus Pharma To Acquire Adamas Pharma For Total Consideration Up To $9.10/shr
    0
    • Adamas ? is it worths to entry ?
      0
      • Pressure to discuss the sale of the company seems to be growing up. https://chn.ge/2OEI2kD
        0
        • All 8 analyst covering ADMS recommend "buy." The average target price consensus for the next 12 months is $34 which is 110% ROI at its current price of $16.16.
          0
          • revenue is going to increase exponentially once this parkinsons drug gets out in circulation in January 18 .. that will be good for top and bottom line numbers come earning seasons.$$$$$. and mist of all definitely great for patients suffering.
            0
          • Huh, so price targets me nothing. The more you know (it's not getting anywhere near $30 in the next 3 months)
            0